ArticleJournal of gastroenterology2026

Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease: a multi-center cohort study.

Ryusuke Nambu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.